Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 7/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9570634 | 0.88 | PLA2G2A (0.46) | MAPTPLA2G2ALTA4HL3MBTL1HPGD | |
| SCHEMBL5727200 | 0.87 | MAPT (0.34) | MAPTLTA4HHPGDLMNAHTT | |
| SCHEMBL24169276 | 0.85 | MAPT (0.57) | MAPTPLA2G2ALTA4HL3MBTL1HPGD | |
| SCHEMBL11534430 | 0.80 | DAO (0.33) | NPC1RAB9A | |
| SCHEMBL6150323 | 0.78 | LTA4H (0.47) | MAPTLTA4HHPGDLMNASMN1; SMN2 | |
| SCHEMBL8844670 | 0.77 | LTA4H (0.40) | MAPTLTA4HL3MBTL1HTT | |
| SCHEMBL10574172 | 0.76 | HPGD (0.48) | LTA4HHPGD | |
| SCHEMBL6505678 | 0.75 | NR1H2 (0.41) | MAPTL3MBTL1LMNA | |
| SCHEMBL8534048 | 0.75 | GRIN1 (0.52) | LTA4H | |
| SCHEMBL1233605 | 0.73 | MAOB (0.40) | MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1502590-B1 | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes | SERVIER LAB (FR) | 2006-12-20 | — | — | EP | disclosed |
| US-7071221-B2 | Heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2006-07-04 | — | — | US | disclosed |
| US-20050026973-A1 | New heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2005-02-03 | — | — | US | disclosed |
| EP-1502590-A1 | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes | Les Laboratoires Servier (FR) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026973-A1 | New heterocyclic oxime compounds | CBR3, CBR1, CYB5R3 | MAPT 4285/4885PLA2G2A 4607/4885LTA4H 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.